Sabine Tejpar

40.5k total citations · 10 hit papers
214 papers, 15.5k citations indexed

About

Sabine Tejpar is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sabine Tejpar has authored 214 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Oncology, 84 papers in Pathology and Forensic Medicine and 70 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sabine Tejpar's work include Colorectal Cancer Treatments and Studies (124 papers), Genetic factors in colorectal cancer (76 papers) and Cancer Genomics and Diagnostics (53 papers). Sabine Tejpar is often cited by papers focused on Colorectal Cancer Treatments and Studies (124 papers), Genetic factors in colorectal cancer (76 papers) and Cancer Genomics and Diagnostics (53 papers). Sabine Tejpar collaborates with scholars based in Belgium, Switzerland and United States. Sabine Tejpar's co-authors include Eric Van Cutsem, Mauro Delorenzi, Wendy De Roock, Philippe Rougier, Christopher Stroh, G. Bodoky, Claus-Henning Köhne, Fred T. Bosman, Fortunato Ciardiello and Bart Biesmans and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Sabine Tejpar

198 papers receiving 15.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. profile →
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

2009 893 citations Arnaud Roth, Sabine Tejpar et al. Journal of Clinical Oncology profile →
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 660 citations Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology profile →
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

2017 657 citations Justin Guinney, Sabine Tejpar et al. profile →
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

2015 578 citations Eric Van Cutsem, Heinz‐Josef Lenz et al. Journal of Clinical Oncology profile →
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 573 citations Wendy De Roock, Hubert Piessevaux et al. profile →
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 ( SMAD4)

2004 534 citations Eric Legius, Sabine Tejpar et al. profile →
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

2014 477 citations Edoardo Missiaglia, Eva Budínská et al. Annals of Oncology profile →
Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus

2015 376 citations Philippe Rougier, Sabine Tejpar et al. profile →
Microbiome confounders and quantitative profiling challengepredicted microbial targets in colorectal cancer development

2024 51 citations Sabine Tejpar et al. profile →

Peers

Countries citing papers authored by Sabine Tejpar

Since Specialization

Citations

This map shows the geographic impact of Sabine Tejpar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Tejpar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Tejpar more than expected).

Fields of papers citing papers by Sabine Tejpar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine Tejpar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Tejpar. The network helps show where Sabine Tejpar may publish in the future.

Co-authorship network of co-authors of Sabine Tejpar

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Tejpar. A scholar is included among the top collaborators of Sabine Tejpar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Tejpar. Sabine Tejpar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response 2024 ·Nature Reviews Clinical Oncology ·Christopher J.M. Williams, (unknown), Pashtoon Murtaza Kasi, Jenny F. Seligmann, Campbell S.D. Roxburgh, Gary Middleton, Sabine Tejpar	2
2	Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response 2024 ·Nature Reviews Clinical Oncology ·Christopher J.M. Williams, (unknown), Pashtoon Murtaza Kasi, Jenny F. Seligmann, Campbell S.D. Roxburgh, Gary Middleton, Sabine Tejpar	25
3	Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Pratyaksha Wirapati, Yourae Hong, Leslie Samuel, Jayesh Desai, (unknown), Zacharenia Saridaki, David Cunningham, Sabine Tejpar, Petros Tsantoulis	0
4	A single-sample gene-expression classifier for the intrinsic consensus molecular subtypes in colorectal cancer. 2024 ·Journal of Clinical Oncology ·Petros Tsantoulis, Yourae Hong, Pratyaksha Wirapati, (unknown), (unknown), Thomas McKee, Sabine Tejpar	0
5	Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor lines 2024 ·iScience ·(unknown), Yoshihito Kano, Yosuke Yoneyama, (unknown), Satoshi Watanabe, Sakura Kirino, (unknown), Yourae Hong, Aleksandra Ostapiuk, Pavlo Lutsik, Iichiroh Onishi, Shinichi Yamauchi, (unknown), Go Ito, Yusuke Kinugasa, Kenichi Ohashi, Mamoru Watanabe, Ryuichi Okamoto, Sabine Tejpar, Shiro Yui	3
6	Targeting conserved TIM3 ⁺ VISTA ⁺ tumor-associated macrophages overcomes resistance to cancer immunotherapy 2024 ·Science Advances ·Isaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, Raquel S. Laureano, Jannes Govaerts, Rosa Trotta, Samantha Pretto, (unknown), (unknown), (unknown), Maarten Jacquemyn, (unknown), Louis Boon, Susan Schlenner, Sabine Tejpar, Dirk Daelemans, Massimiliano Mazzone, Abhishek D. Garg	22
7	Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) 2023 ·Autoimmunity Reviews ·Xavier Bossuyt, Jean‐Baptiste Vulsteke, Jan Van Elslande, Louis Boon, (unknown), (unknown), Glynis Frans, (unknown), Sébastien Carpentier, Sabine Tejpar, Hans Wildiers, Daniël Blockmans, Ellen De Langhe, Pieter Vermeersch, Rita Derua	4
8	181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative 2023 ·Annals of Oncology ·Philippe Aftimos, Kevin Punie, Lore Decoster, Cédric van Marcke, Aline Hébrant, Gordana Raicevic, Els Van Valckenborgh, Brigitte Maes, (unknown), Joëlle Collignon, (unknown), (unknown), Wim Demey, Sabine Tejpar, Marc Peeters, J-L. Canon, Willem Lybaert, Jeroen Mebis, Sylvie Rottey, Jacques De Grève	0
9	Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study 2023 ·ESMO Open ·Sofie Joris, Hannelore Denys, Joëlle Collignon, Marika Rasschaert, Daphné t’Kint de Roodenbeke, François P. Duhoux, Jean Luc Canon, Sabine Tejpar, Jeroen Mebis, Lore Decoster, Philippe Aftimos, Jacques De Grève	18
10	BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression 2016 ·Clinical Cancer Research ·David Barras, Edoardo Missiaglia, Pratyaksha Wirapati, Oliver M. Sieber, Robert N. Jorissen, (unknown), Peter L. Molloy, Ian T. Jones, Stephen McLaughlin, Peter Gibbs, Justin Guinney, Iris Simón, Arnaud Roth, Fred T. Bosman, Sabine Tejpar, Mauro Delorenzi	161
11	Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer 2016 ·Clinical Cancer Research ·Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fred T. Bosman, Roberto Fiocca	62
12	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer breakdown → 2015 ·Journal of Clinical Oncology ·Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, I. Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J. Han van Krieken, Fortunato Ciardiello	578
13	DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer 2015 ·Clinical Cancer Research ·Sune Boris Nygård, Ben Vainer, (unknown), Fred T. Bosman, Sabine Tejpar, Arnaud Roth, Mauro Delorenzi, Nils Brünner, Eva Budínská	12
14	Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology 2015 ·Marc Van den Bulcke, (unknown), Roberto Salgado, (unknown), Harlinde De Schutter, Anouk Waeytens, (unknown), Sabine Tejpar, Jeroen Van Houdt, (unknown), Brigitte Maes, Frank Hulstaert	5
15	A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy 2014 ·Clinical Cancer Research ·Zenia Saridaki, Joanne B. Weidhaas, Heinz‐Josef Lenz, Pierre Laurent‐Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar	52
16	Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer 2013 ·Clinical Cancer Research ·Erin M. Coffee, Anthony C. Faber, Jatin Roper, Mark J. Sinnamon, Gautam Goel, (unknown), (unknown), Loredana Vecchione, Veerle de Vriendt, Barbara Weinstein, Roderick T. Bronson, Sabine Tejpar, Ramnik J. Xavier, Jeffrey A. Engelman, Eric S. Martin, Kenneth E. Hung	70
17	PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer 2009 ·Clinical Cancer Research ·Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar	241
18	Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study 2008 ·Clinical Cancer Research ·Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, (unknown), Maria Dêbiec‐Rychter, Jean–Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar	129
19	The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab 2008 ·Ghent University Academic Bibliography (Ghent University) ·Sabine Tejpar, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, Gert De Hertogh, Wendy De Roock, Johannes Nippgen, (unknown), Christopher Stroh, (unknown)	4
20	Predictive Testing for Hereditary Nonpolyposis Colorectal Cancer: Subjective Perception Regarding Colorectal and Endometrial Cancer, Distress, and Health-related Behavior at One Year Post-Test 2005 ·Genetic Testing ·Erna Claes, Lieve Denayer, Gerry Evers‐Kiebooms, Andrea Boogaerts, (unknown), Sabine Tejpar, Koenraad Devriendt, Eric Legius	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact